Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies

Coutre, Steven E.; Byrd, John C.; Hillmen, Peter; Barrientos, Jacqueline C.; Barr, Paul M.; Devereux, Stephen; Robak, Tadeusz; Kipps, Thomas J.; Schuh, Anna; Moreno, Carol; Furman, Richard R.; Burger, Jan A.; O’Dwyer, Michael; Ghia, Paolo; Valentino, Rudolph; Chang, Stephen; Dean, James P.; James, Danelle F.; O’Brien, Susan M.

doi:10.1182/bloodadvances.2018028761

Cited by 137Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentPharmacovigilance and Adverse Drug Reactions

The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.

Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies

Open access

Coutre, Steven E., Byrd, John C., Hillmen, Peter, Barrientos, Jacqueline C., Barr, Paul M., Devereux, Stephen, Robak, Tadeusz, Kipps, Thomas J., Schuh, Anna, Moreno, Carol, Furman, Richard R., Burger, Jan A., O’Dwyer, Michael, Ghia, Paolo, Valentino, Rudolph, Chang, Stephen, Dean, James P., James, Danelle F., O’Brien, Susan M.·2019·Blood Advances

DOI 10.1182/bloodadvances.2018028761PMC PMC6595265

Open this paper in CoChat — free account

Abstract

Ibrutinib, a first-in-class once-daily oral Bruton tyrosine kinase inhibitor indicated for chronic lymphocytic leukemia (CLL), is continued until progressive disease or unacceptable toxicity. We conducted an integrated safety analysis of single-agent ibrutinib from randomized phase 3 studies PCYC-1112 (RESONATE, n = 195) and PCYC-1115/1116 (RESONATE-2, n = 135), and examined longer-term safety separately in the phase 1b/2 PCYC-1102/1103 study (n = 94, 420 mg/d). In the integrated analysis (ibrutinib treatment up to 43 months), the most common adverse events (AEs) were primarily grade 1/2; diarrhea (n = 173, 52% any-grade; n = 15, 5% grade 3) and fatigue (n = 119, 36% any-grade; n = 10, 3% grade 3). The most common grade 3/4 AEs were neutropenia (n = 60, 18%) and pneumonia (n = 38, 12%). Over time, prevalence of AEs of interest (diarrhea, fatigue, grade ≥3 infection, bleeding, and neutropenia) trended down; prevalence of hypertension increased, but incidence decreased after year 1. AEs led to dose reductions in 42 (13%) patients and permanent discontinuations in 37 (11%); dose modifications due to AEs were most common during year 1 and decreased in frequency thereafter. The most common AEs (preferred term) contributing to discontinuation included pneumonia (n = 4), anemia (n = 3), and atrial fibrillation (n = 3). With long-term follow-up on PCYC-1102/1103 (ibrutinib treatment up to 67 months), grade 3/4 AEs were generally similar to those in the integrated analysis. Overall, A…

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2018028761

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

After 4 years of treatment with ibrutinib, up to 40% of patients eventually encounter treatment failure due to the development of resistance or intolerance.
“However, after 4 years of treatment with ibrutinib, up to 40% of patients eventually encounter treatment failure due to the development of resistance or intolerance (8).”
From Resistance Mechanisms and Approach to Chronic Lymphocytic Leukemia after BTK Inhibitor Therapy (2025) · cites this paper as [8]

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
Hallek, M. J., Cheson, B. D., Catovsky, D., Caligaris‐Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M. J., Montserrat, E., Rai, K. R., et al. (2008) · Blood · doi:10.1182/blood-2007-06-093906 · Cited by 3,782
Self-citation
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Self-citation
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd, J. C., Brown, J. R., O'Brien, S. M., Barrientos, J. C., Kay, N. E., Reddy, N. M., Coutre, S. E., Tam, C. S. L., Mulligan, S. P., Jaeger, U., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400376 · Cited by 1,665
Self-citation
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
Burger, J. A., Tedeschi, A., Barr, P. M., Robak, T., Owen, C., Ghia, P., Bairey, O., Hillmen, P., Bartlett, N. L., Li, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509388 · Cited by 1,587
Self-citation
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Goede, V., Fischer, K., Busch, R. M., Engelke, A., Eichhorst, B. F., Wendtner, C., Chagorova, T., de la Serna, J., Dilhuydy, M., Illmer, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313984 · Cited by 1,530
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
Fischer, K., Bahlo, J., Fink, A. M., Goede, V., Herling, C., Cramer, P., Langerbeins, P., von Tresckow, J., Engelke, A., Maurer, C., et al. (2015) · Blood · doi:10.1182/blood-2015-06-651125 · Cited by 1,300
Self-citation
Opioid Abuse in the United States and Department of Health and Human Services Actions to Address Opioid-Drug-Related Overdoses and Deaths
U.S. Department of Health and Human (2015) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.3109/15360288.2015.1037530 · Cited by 891
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib
Byrd, J. C., Furman, R. R., Coutre, S. E., Burger, J. A., Blum, K. A., Coleman, M., Wierda, W. G., Jones, J. A., Zhao, W., Heerema, N. A., et al. (2015) · Blood · doi:10.1182/blood-2014-10-606038 · Cited by 674
Self-citation
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
O'Brien, S. M., Furman, R. R., Coutre, S. E., Sharman, J. P., Burger, J. A., Blum, K. A., Grant, B., Richards, D., Coleman, M., Wierda, W. G., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70513-8 · Cited by 469
Self-citation
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Mato, A. R., Nabhan, C., Thompson, M. C., Lamanna, N., Brander, D. M., Hill, B. T., Howlett, C., Skarbnik, A. P. Z., Cheson, B. D., Zent, C. S., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.182907 · Cited by 464
Self-citation
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
Wang, M. L., Blum, K. A., Martin, P., Goy, A. H., Auer, R. L., Kahl, B. S., Jurczak, W. J., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2015) · Blood · doi:10.1182/blood-2015-03-635326 · Cited by 412
Self-citation
Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling
McMullen, J. R., Boey, E. J. H., Ooi, J. Y. Y., Seymour, J. F., Keating, M. J., & Tam, C. S. L. (2014) · Blood · doi:10.1182/blood-2014-10-604272 · Cited by 410
Perturbation of the normal immune system in patients with CLL
Forconi, F., & Moss, P. A. H. (2015) · Blood · doi:10.1182/blood-2015-03-567388 · Cited by 387
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
O'Brien, S. M., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Sharman, J. P., Wierda, W. G., Jones, J. A., Zhao, W., et al. (2018) · Blood · doi:10.1182/blood-2017-10-810044 · Cited by 387
Self-citation
Infectious Complications of Chronic Lymphocytic Leukemia
Wadhwa, P. D., & Morrison, V. A. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.12.013 · Cited by 276
Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways
Chamilos, G., Lionakis, M. S., & Kontoyiannis, D. P. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix687 · Cited by 267
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
Brown, J. R., Hillmen, P., O’Brien, S. J., Barrientos, J. C., Reddy, N. M., Coutre, S. E., Tam, C. S. L., Mulligan, S. P., Jaeger, U., Barr, P. M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.175 · Cited by 244
Self-citation
Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia
Thurmes, P. J., Call, T. G., Slager, S. L., Zent, C. S., Jenkins, G. D., Schwager, S. M., Bowen, D. A., Kay, N. E., & Shanafelt, T. D. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701724785 · Cited by 202
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL
Badoux, X. C. A., Keating, M. J., Wang, X., O'Brien, S. M., Ferrajoli, A., Faderl, S. H., Burger, J. A., Koller, C. A., Lerner, S. A., Kantarjian, H. M., et al. (2011) · Blood · doi:10.1182/blood-2010-08-304683 · Cited by 195
Self-citation
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib
Ahn, I. E., Jerussi, T., Farooqui, M. Z. H., Tian, X., Wiestner, A. U., & Gea‐Banacloche, J. (2016) · Blood · doi:10.1182/blood-2016-06-722991 · Cited by 165
PCN122 DEVELOPMENT OF THE PATIENT-REPORTED VERSION OF THE COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (PRO-CTCAE)
Basch, E., Reeve, B. B., Cleeland, C. S., Sloan, J., Schrag, D., Atkinson, T., Mendoza, T. R., Hay, J., Abernethy, A. P., Minasian, L. M., et al. (2010) · Value in Health · doi:10.1016/s1098-3015(11)72017-4 · Cited by 163
Frequency and type of serious infections in fludarabine‐refractory B‐cell chronic lymphocytic leukemia and small lymphocytic lymphoma
Perkins, J. G., Flynn, J. M., Howard, R. S., & Byrd, J. C. (2002) · Cancer · doi:10.1002/cncr.0680 · Cited by 156
Self-citation
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL
Barr, P. M., Brown, J. R., Hillmen, P., O'Brien, S. M., Barrientos, J. C., Reddy, N. M., Coutre, S. E., Mulligan, S. P., Jaeger, U., Furman, R. R., et al. (2017) · Blood · doi:10.1182/blood-2016-12-737346 · Cited by 148
Self-citation
Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance
Winthrop, K. L., Novosad, S., Baddley, J. W., Calabrese, L. H., Chiller, T. M., Polgreen, P. M., Bartalesi, F., Lipman, M. C. I., Xavier Mariette, A., Lortholary, O., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207841 · Cited by 142
Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force
Stauder, R., Eichhorst, B. F., Hamaker, M. E., Kaplanov, K. D., Morrison, V. A., Österborg, A., Poddubnaya, I. V., Woyach, J. A., Shanafelt, T. D., Smolej, L., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw547 · Cited by 109
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Coutre, S. E., Furman, R. R., Flinn, I. W., Burger, J. A., Blum, K. A., Sharman, J. P., Jones, J. A., Wierda, W. G., Zhao, W., Heerema, N. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1431 · Cited by 61
Self-citation
Infections in chronic lymphocytic leukemia. Analysis of incidence as a function of length of follow-up.
Molica, S., Levato, D., & Levato, L. (1993) · PubMed · Cited by 44
Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study.
Byrd, J. C., Hillmen, P., O'Brien, S. M., Barrientos, J. C., Reddy, N. M., Coutre, S. E., Tam, C. S. L., Mulligan, S. P., Jaeger, U., Barr, P. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.7510 · Cited by 16
Self-citation
Front-line treatment of patients with chronic lymphocytic leukemia: a systematic review and network meta-analysis
Xu, Y., Fahrbach, K. R., Dorman, E., Baculea, S., Côté, S., Sanden, S. V., & Diels, J. (2017) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2017-0086 · Cited by 9
Survival adjusting for crossover: phase 3 study of ibrutinib vs . chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma
Coutre, S. E., Tedeschi, A., Robak, T., Barr, P. M., Owen, C., Bairey, O., Burger, J. A., Zhou, C., Styles, L. A., James, D. F., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.175380 · Cited by 5
Self-citation

Flagged first, then by citations

1 of the 31 references couldn’t be matched to a known paper.

Sorted by citations

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Mato, A. R., Shah, N. N., Jurczak, W. J., Cheah, C. Y., Pagel, J. M., Woyach, J. A., Fakhri, B., Eyre, T. A., Lamanna, N., Patel, M. R., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00224-5 · Cited by 486
Self-citation
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
Barr, P. M., Owen, C., Robak, T., Tedeschi, A., Bairey, O., Burger, J. A., Hillmen, P., Coutre, S. E., Dearden, C. E., Grosicki, S., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006434 · Cited by 292
Self-citation
Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
Wen, T., Wang, J., Shi, Y., Qian, H., & Liu, P. (2020) · Leukemia · doi:10.1038/s41375-020-01072-6 · Cited by 276
Managing toxicities of Bruton tyrosine kinase inhibitors
Lipsky, A. H., & Lamanna, N. (2020) · Hematology · doi:10.1182/hematology.2020000118 · Cited by 174
Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia
Treon, S. P., Meid, K., Gustine, J. N., Yang, G., Xu, L., Liu, X., Patterson, C. J., Hunter, Z. R., Branagan, A. R., Laubach, J. P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00555 · Cited by 160
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study
Buske, C., Tedeschi, A., Trotman, J., García‐Sánz, R., Macdonald, D. A., Leblond, V., Mahé, B., Herbaux, C., Matous, J., Tam, C. S. L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00838 · Cited by 125
Dermatological Toxicities of Bruton’s Tyrosine Kinase Inhibitors
Sibaud, V., Beylot-Barry, M., Protin, C. A., Vigarios, É., Récher, C., & Ysebaert, L. (2020) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00535-x · Cited by 124
Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies
Gu, D., Tang, H., Wu, J., Li, J., & Miao, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01049-7 · Cited by 100
Acalabrutinib in treatment-naive chronic lymphocytic leukemia
Byrd, J. C., Woyach, J. A., Furman, R. R., Martin, P., O'Brien, S. M., Brown, J. R., Stephens, D. M., Barrientos, J. C., Devereux, S., Hillmen, P., et al. (2021) · Blood · doi:10.1182/blood.2020009617 · Cited by 100
Self-citation
ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Hillmen, P., Brown, J. R., Eichhorst, B. F., Lamanna, N., O'Brien, S. M., Qiu, L., Salmi, T., Hilger, J. D., Wu, K., Cohen, A. C., et al. (2020) · Future Oncology · doi:10.2217/fon-2019-0844 · Cited by 83
Self-citation
Targeting Bruton’s Tyrosine Kinase in CLL
Ahn, I. E., & Brown, J. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.687458 · Cited by 82
Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL)
Mauro, F. R., Giannarelli, D., Galluzzo, C. M., Vitale, C., Visentin, A., Riemma, C., Rosati, S., Porrazzo, M., Pepe, S., Coscia, M., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0884-z · Cited by 79
Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus
Henze, L., Buhl, C., Sandherr, M., Cornely, O. A., Heinz, W., Khodamoradi, Y., Kiderlen, T. R., Koehler, P. A., Seidler, A., Sprute, R., et al. (2022) · Annals of Hematology · doi:10.1007/s00277-021-04746-y · Cited by 77
Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib
Ran, F., Liu, Y., Wang, C., Xu, Z., Zhang, Y., Liu, Y., Zhao, G., & Ling, Y. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114009 · Cited by 76
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients
Brown, J. R., Byrd, J. C., Ghia, P., Sharman, J. P., Hillmen, P., Stephens, D. M., Sun, C., Jurczak, W. J., Pagel, J. M., Ferrajoli, A., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.278901 · Cited by 66
Self-citation
Non-Covalent BTK Inhibitors—The New BTKids on the Block for B-Cell Malignancies
Lewis, K. L., & Cheah, C. Y. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080764 · Cited by 57
Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: A single-arm meta-analysis
Hou, K., Yu, Z., Jia, Y., Fang, H., Shao, S., Huang, L., & Feng, Y. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103010 · Cited by 52
Inhibition of effector B cells by ibrutinib in systemic sclerosis
Einhaus, J. F., Pecher, A., Asteriti, E., Schmid, H., Secker, K.-A., Duerr‐Stoerzer, S., Keppeler, H., Klein, R., Schneidawind, C., Henes, J., et al. (2020) · Arthritis Research & Therapy · doi:10.1186/s13075-020-02153-8 · Cited by 42
Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies
Maharaj, K. K., Uriepero, A., Sahakian, E., & Pinilla-Ibarz, J. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.943354 · Cited by 41
Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial
Trotman, J., Buske, C., Tedeschi, A., Matous, J., Macdonald, D. B., Tam, C. S. L., Tournilhac, O., Ma, S., Treon, S. P., Oriol, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1497 · Cited by 39
Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical
Dong, R., Yan, Y., Zeng, X., Lin, N., & Tan, B. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s377697 · Cited by 39
Management of Ibrutinib Toxicities: a Practical Guide
Lasica, M., & Tam, C. S. L. (2020) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-020-00576-3 · Cited by 38
A Phase III Study of Zanubrutinib Plus Rituximab Versus Bendamustine Plus Rituximab in Transplant-Ineligible, Untreated Mantle Cell Lymphoma
Dreyling, M. H., Tam, C. S. L., Wang, M. L., Smith, S. D., Ladetto, M., Huang, H., Novotny, W. F., Co, M., Romano, A., Holmgren, E. B., et al. (2020) · Future Oncology · doi:10.2217/fon-2020-0794 · Cited by 36
Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors
Fleming, M. R., Xiao, L., Jackson, K. D., Beckman, J. A., Barac, A., & Moslehi, J. J. (2021) · Circulation Research · doi:10.1161/circresaha.121.318259 · Cited by 36
Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia
Hampel, P. J., Call, T. G., Rabe, K. G., Ding, W., Muchtar, E., Kenderian, S. S., Wang, Y., Leis, J. F., Witzig, T. E., Koehler, A. B., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0388 · Cited by 35
Hypertensive Cardiotoxicity in Cancer Treatment—Systematic Analysis of Adjunct, Conventional Chemotherapy, and Novel Therapies—Epidemiology, Incidence, and Pathophysiology
Chung, R., Tyebally, S. M., Chen, D. H., Kapil, V., Walker, J. M., Addison, D., Ismail-Khan, R. R., Guha, A., & Ghosh, A. K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103346 · Cited by 35
Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect
Wang, H., Guo, H., Yang, J., Liu, Y., Liu, X., Zhang, Q., & Zhou, K. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00315-9 · Cited by 35
Current Perspectives on Therapy for Chronic Lymphocytic Leukemia
Awan, F. T., Al‐Sawaf, O., Fischer, K., & Woyach, J. A. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_279099 · Cited by 30
The Use of Bruton’s Tyrosine Kinase Inhibitors to Treat Allergic Disorders
Dispenza, M. C. (2021) · Current Treatment Options in Allergy · doi:10.1007/s40521-021-00286-y · Cited by 30
Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on
Molica, S., Matutes, E., Tam, C. S. L., & Polliack, A. (2019) · Hematological Oncology · doi:10.1002/hon.2695 · Cited by 29
Management of cardiovascular complications of bruton tyrosine kinase inhibitors
Tang, C. P. S., Lip, G. Y. H., McCormack, T., Lyon, A. R., Hillmen, P., Iyengar, S., Martínez‐Calle, N., Parry‐Jones, N., Patten, P., Schuh, A., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17788 · Cited by 29
Self-citation
Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia
Roeker, L. E., Yazdy, M. S., Rhodes, J. M., Goodfriend, J. M., Narkhede, M. S., Carver, J. R., & Mato, A. R. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.16326 · Cited by 28
Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib
Hampel, P. J., Cherng, H.-J. J., Call, T. G., Ding, W., Khanlari, M., McPhail, E. D., Miranda, R. N., Lin, P., Tawbi, H. A., Ferrajoli, A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002454 · Cited by 27
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Mauro, F. R., Giannarelli, D., Visentin, A., Reda, G., Sportoletti, P., Frustaci, A. M., Chiarenza, A., Ciolli, S., Vitale, C., Laurenti, L., et al. (2021) · Cancers · doi:10.3390/cancers13133240 · Cited by 27
Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances
Schaff, L. R., Nayak, L., & Grommes, C. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2333985 · Cited by 24
Onco-hypertension: An Emerging Specialty
Gudsoorkar, P. S., Ruf, R., Adnani, H., Safdar, K. A., & Sparks, M. A. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.09.011 · Cited by 24
Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension—Mechanisms and Mitigation
Butel-Simoes, L. E., Haw, T. J., Williams, T. D., Sritharan, S., Gadre, P., Herrmann, S. M., Herrmann, J., Ngo, D. T. M., & Sverdlov, A. L. (2023) · Hypertension · doi:10.1161/hypertensionaha.122.17947 · Cited by 23
Current Treatment of Refractory/Relapsed Chronic Lymphocytic Leukemia: A Focus on Novel Drugs
Smolewski, P., & Robak, T. (2020) · Acta Haematologica · doi:10.1159/000510768 · Cited by 23
Self-citation
Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)
Mato, A. R., Davids, M. S., Sharman, J. P., Roeker, L. E., Kay, N. E., Kater, A. P., Rogers, K. A., Thompson, M. C., Rhodes, J. M., Goy, A. H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1237 · Cited by 22
Self-citation
Long‐term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity
Gordon, M. J., Jones, J. E., George, B., Peterson, C. B., Burger, J. A., Jain, N., Keating, M. J., Wierda, W. G., Durand, J., & Ferrajoli, A. (2023) · Cancer · doi:10.1002/cncr.34787 · Cited by 22
Self-citation
Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis
Nocco, S. E., Andriano, T. M., Bose, A., Chilov, M., Godwin, K., Dranitsaris, G., Wu, S., Lacouture, M. E., Roeker, L. E., Mato, A. R., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103696 · Cited by 21
BTK Inhibitors in Chronic Lymphocytic Leukemia
Gaballa, S. R., & Pinilla-Ibarz, J. A. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00645-1 · Cited by 21
Distinct Age-Related Clinical Features and Risk Assessment in Chinese With Chronic Lymphocytic Leukemia
Tian, Z., Liu, M., Fang, X., Zhou, X., Li, P., Li, Y., Zhang, L., Liu, F., Zhang, Y., & Wang, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.885150 · Cited by 20
Secondary antibody deficiency in chronic lymphocytic leukemia and non-Hodgkin lymphoma: Recommendations from an international expert panel
Jolles, S. R. A., Giralt, S., Kerre, T. C. C., Lazarus, H. M., Mustafa, S. S., Papanicolaou, G. A., Reiser, M., Ria, R., Vinh, D. C., & Wingard, J. R. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.101020 · Cited by 20
Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents
Galitzia, A., Maccaferri, M., Mauro, F. R., Murru, R., & Marasca, R. (2024) · Cancers · doi:10.3390/cancers16111996 · Cited by 18
Onconephrology 2022: An Update
Bonilla, M. A., Gudsoorkar, P. S., Wanchoo, R., Herrmann, S. M., & Jhaveri, K. D. (2022) · Kidney360 · doi:10.34067/kid.0001582022 · Cited by 18
BTKi-induced cardiovascular toxicity in CLL: Risk mitigation and management strategies
Kozarac, S., Vuković, V., Fradley, M. G., & Antic, D. A. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101268 · Cited by 17
BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL
Rogers, A. M., & Woyach, J. A. (2020) · Therapeutic Advances in Hematology · doi:10.1177/2040620720912990 · Cited by 16
Beyond ibrutinib: novel BTK inhibitors for the treatment of chronic lymphocytic leukemia
Perutelli, F., Montalbano, M. C., Boccellato, E., Coscia, M., & Vitale, C. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000897 · Cited by 15
Diverse landscape of dermatologic toxicities from small‐molecule inhibitor cancer therapy
Seervai, R. N. H., Cho, W. C., Chu, E. Y., Marques-Piubelli, M. L., Ledesma, D. A., Richards, K. N., Heberton, M. M., Nelson, K. C., Nagarajan, P., Torres-Cabala, C. A., et al. (2021) · Journal of Cutaneous Pathology · doi:10.1111/cup.14145 · Cited by 14
Utilizing Real-World Evidence (RWE) to Improve Care in Chronic Lymphocytic Leukemia: Challenges and Opportunities
Islam, P., & Mato, A. R. (2020) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-020-00584-3 · Cited by 14
Chronic lymphocytic leukaemia Australasian consensus practice statement
Anderson, M. A., Bennett, R., Badoux, X. C. A., Best, G., Chia, N., Cochrane, T., Cull, G., Crassini, K. R., Harrup, R. A., Jackson, S., et al. (2023) · Internal Medicine Journal · doi:10.1111/imj.16207 · Cited by 13
Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib
Molica, S., Gianfelici, V., & Levato, L. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1724282 · Cited by 13
Onco-hypertension: Overview of hypertension with anti-cancer agents
Ruf, R., Yarandi, N., Ortiz-Melo, D. I., & Sparks, M. A. (2021) · Journal of Onco-Nephrology · doi:10.1177/23993693211001374 · Cited by 13
Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib
Bye, A. P., Kriek, N., Sage, T., Rawlings, S., Prodger, C. F., Kesavan, M., Lees, C., Booth, S., Cowen, L. G., Shefferd, K., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.281402 · Cited by 13
Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies
Smyth, E., Cheah, C. Y., & Seymour, J. F. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102510 · Cited by 13
Bruton Tyrosine Kinase Inhibitors for the Frontline Treatment of Chronic Lymphocytic Leukemia
Banerji, V., Aw, A., Robinson, S., Doucette, S., Christofides, A., & Sehn, L. H. (2020) · Current Oncology · doi:10.3747/co.27.6795 · Cited by 12
Bruton’s Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia
Naylor‐Adamson, L., Chacko, A. R., Booth, Z., Caserta, S., Jarvis, J., Khan, S., Hart, S. P., Rivero, F., Allsup, D. J., & Arman, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.766272 · Cited by 11
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial
Michallet, A., Letestu, R., Garff‐Tavernier, M. L., Campos, L., Ticchioni, M., Dilhuydy, M., Morisset, S., Rouille, V., Mahé, B., Laribi, K., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009594 · Cited by 11
High risk of infection in ‘real‐world’ patients receiving ibrutinib, idelalisib or venetoclax for mature B‐cell leukaemia/lymphoma
Tey, A., Schwarer, J., Raffa, R., Shi, E., Paul, E. M., Opat, S., Dendle, C., & Shortt, J. (2023) · European Journal Of Haematology · doi:10.1111/ejh.13928 · Cited by 10
Frontline Management of CLL in 2021
Brem, E. A., & O'Brien, S. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00258 · Cited by 10
Self-citation
BTK inhibitors: safety + efficacy = outcome
Niemann, C. U. (2023) · Blood · doi:10.1182/blood.2023020974 · Cited by 10
Managing novel therapies and concomitant medications in chronic lymphocytic leukemia: key challenges
Kozarac, S., Ivanović, J., Mitrovic, M., Tomić-Vujović, K., Arsenović, I., Suvajdžić, N., Bogdanovic, A. D., Vidović, A., Todorović, M., Bila, J., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1517972 · Cited by 9
Cystoid macular edema secondary to ibrutinib
Ben-Avi, R., Dori, D., & Chowers, I. (2022) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2022.101436 · Cited by 9
Is a BTKi or BCL2i preferable for first “novel” therapy in CLL? The case for BTKis
Brem, E. A., & O'Brien, S. M. (2021) · Blood Advances · doi:10.1182/bloodadvances.2019001204 · Cited by 9
Self-citation
Pirtobrutinib in the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma
Ibrahim, S., Pham, N., Sahni, A., Sekeres, S., Cool, A., Taylor, J. M., & Coombs, C. C. (2025) · Future Oncology · doi:10.1080/14796694.2025.2567834 · Cited by 8
Evaluation of infectious morbidity due to BTK inhibitors in indolent B-cell lymphomas: latest research findings and systematic analysis
Dasanu, C. A., Mann, S. K., Baidya, M., Mdluli, X., Stapleton, A. E., & Codreanu, I. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2390121 · Cited by 8
Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy
Lamanna, N., Tam, C. S. L., Woyach, J. A., Alencar, A. J., Palomba, M. L., Zinzani, P. L., Flinn, I. W., Fakhri, B., Cohen, J. B., Kontos, A., et al. (2024) · eJHaem · doi:10.1002/jha2.1013 · Cited by 8
Identification of Genes Whose Expression Overlaps Age Boundaries and Correlates with Risk Groups in Paediatric and Adult Acute Myeloid Leukaemia
Davis, L., Mills, K., Orchard, K. H., & Guinn, B. (2020) · Cancers · doi:10.3390/cancers12102769 · Cited by 8
In silico analysis of atrial fibrillation and hypertension mechanism of action secondary to ibrutinib/acalabrutinib in chronic lymphocytic leukemia
Córdoba, R., Bayés‐Genís, A., Muntañola, A., Colomer, D., Castro, J., Leiva, C., Álvarez, E., & Zatarain‐Nicolás, E. (2025) · Scientific Reports · doi:10.1038/s41598-025-07756-2 · Cited by 7
Incidence and prophylaxis of herpes zoster in relapsed or refractory B-cell lymphoma patients after CD19-specific CAR-T cell therapy
Liu, H., Li, P., Zhao, A., Lei, W., Liang, A., & Qian, W. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.2010062 · Cited by 7
Outcome of cancer patients after atrial fibrillation ablation: Insights from the China‐AF registry
Peng, X., He, L., Liu, N., Ruan, Y., Zhao, X., Guo, X., Wang, W., Li, S., Tang, R., Sang, C., et al. (2023) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.14830 · Cited by 7
Resistance Mechanisms and Approach to Chronic Lymphocytic Leukemia after BTK Inhibitor Therapy
Gruessner, C., Wiestner, A., & Sun, C. (2025) · Leukemia & Lymphoma · doi:10.1080/10428194.2025.2466101 · Cited by 6
“However, after 4 years of treatment with ibrutinib, up to 40% of patients eventually encounter treatment failure due to the development of resistance or intolerance [8].”
Management of infections for patient treated with ibrutinib in clinical practice
Baratè, C., Scortechini, I., Ciofini, S., Picardi, P., Angeletti, I., Loscocco, F., Sanna, A., Isidori, A., & Sportoletti, P. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1428464 · Cited by 6
Posaconazole‐ibrutinib interaction cannot be avoided by staggered dosing: How to optimize ibrutinib dose during posaconazole treatment
Olkkola, A. M., Tapaninen, T., Tornio, A., Hauta‐aho, M., Lapatto‐Reiniluoto, O., Neuvonen, M., Kiiski, J. I., Neuvonen, P. J., Niemi, M., & Backman, J. T. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15932 · Cited by 6
Serum profiling identifies ibrutinib as a treatment option for young adults with B‐cell acute lymphoblastic leukaemia
Jordaens, S., Cooksey, L., Bonney, S. A., Orchard, L., Coutinho, M., Tendeloo, V. F. V., Mills, K., Orchard, K. H., & Guinn, B. (2020) · British Journal of Haematology · doi:10.1111/bjh.16407 · Cited by 6
Chronic lymphoproliferative disorders and secondary cancers in the era of purine analogues and beyond
Harrop, S., Polliack, A., & Tam, C. S. L. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1849682 · Cited by 6
Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post-hoc analysis of a large clinical trial safety database
Brown, J. R., Ghia, P., Jurczak, W. J., Kahl, B. S., Lamanna, N., Robak, T., Shadman, M. S., Tam, C. S. L., Qiu, L., Paik, J. C., et al. (2024) · Haematologica · doi:10.3324/haematol.2023.283846 · Cited by 6
Self-citation
Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance
Omi, A., Nomura, F., Tsujioka, S., Fujino, A., & Akizuki, R. (2022) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.22002 · Cited by 6
Next-generation Bruton tyrosine kinase inhibitors and degraders in the treatment of B-cell malignancies: advances and challenges
Wang, Y., Zhang, Y., Liu, J., Jiang, Y., Li, J., & Shi, W. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06515-7 · Cited by 5
Cutaneous Adverse Effects in Patients Treated with BTK Inhibitors
Robak, E., & Robak, T. (2026) · Cancers · doi:10.3390/cancers18030371 · Cited by 5
Self-citation
Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma
Song, Y., Zhou, K., Yang, S., Hu, J., Zou, D., Gao, S., Pan, L., Wang, T., Yang, H., Zhang, H., et al. (2023) · Investigational New Drugs · doi:10.1007/s10637-023-01376-1 · Cited by 5
Differential modulation of Bruton's tyrosine kinase inhibitor selectivity on platelet GPVI and integrin αIIbβ3 bidirectional signalling via BTK / PLCγ2 / PKCθ affects haemostasis and thrombosis
Zhang, T., Du, S., Han, G., Shi, H., Cheng, Z., Wang, S., Guan, Y., Long, Z., & Xia, Q. (2025) · British Journal of Haematology · doi:10.1111/bjh.70029 · Cited by 4
Towards personalized prevention of Herpes zoster infection in patients with hematologic diseases or hematopoietic stem cell transplant recipients: a position paper from an ad hoc Italian expert panel
Girmenia, C., Ciceri, F., Corradini, P., Cuneo, A., D’Ancona, F. “., Musto, P., Risitano, A. M., Voso, M. T., Venditti, A., & Barosi, G. (2023) · Haematologica · doi:10.3324/haematol.2023.284417 · Cited by 4
Incidence of pneumonia among bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis of clinical trials
Mahadevia, H. J., Ponvilawan, B., & Shrestha, A. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06373-3 · Cited by 4
Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitors
Anderson, M. A., Awan, F. T., Berkahn, L., Crassini, K. R., Lee, H., Marlton, P. V., Mulligan, S. P., Nolan, M. T., Tam, C. S. L., & Sverdlov, A. L. (2025) · Internal Medicine Journal · doi:10.1111/imj.70159 · Cited by 4
How We Manage Patients with Indolent B-Cell Malignancies on Bruton’s Tyrosine Kinase Inhibitors: Practical Considerations for Nurses and Pharmacists
Nixon, S., Duquette, D., Doucette, S., & Larouche, J.-F. (2023) · Current Oncology · doi:10.3390/curroncol30040322 · Cited by 4
New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia
Jordaens, S., Cooksey, L., Boullosa, L. F., Tendeloo, V. F. V., Smits, E., Mills, K., Orchard, K. H., & Guinn, B. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02484-0 · Cited by 4
The Evolution of Targeted Therapies in Chronic Lymphocytic Leukaemia
Gianfelici, V., Levato, L., & Molica, S. (2020) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-020-00586-1 · Cited by 4
Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors
Bose, P., & Gandhi, V. V. (2021) · Faculty Reviews · doi:10.12703/r/10-22 · Cited by 4
Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
Kutsch, N., Pallasch, C. P., Decker, T. W., Hebart, H. F., Chow, K. U., Graeven, U., Kisro, J., Kroeber, A., Tausch, E., Fischer, K., et al. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000729 · Cited by 4
Cost impact of Bruton’s tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia
Kittai, A. S., Patel, D. A., Shafrin, J. T., Zawadzki, N. K., Shetty, V. S., Barqawi, Y. K., & Rhodes, J. M. (2025) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2025-0035 · Cited by 3
Hypertension in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma in ALPINE: a secondary analysis
Rhee, J., Lamanna, N., Aldairy, W., Chen, L., Zhang, J., Ramirez, D., & White, W. B. (2025) · Blood Neoplasia · doi:10.1016/j.bneo.2025.100150 · Cited by 3
A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study
Itsara, A., Rogness, V. M., Samples, L. S., Yuan, C. M., Wang, H., Ahn, I. E., Farooqui, M. Z. H., Tian, X., Sun, C., Tomasulo, E. B., et al. (2025) · Blood · doi:10.1182/blood.2025029971 · Cited by 3
Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma
Siddiqi, T., Coutre, S. E., McKinney, M. S., Barr, P. M., Rogers, K. A., Mokatrin, A., Valentino, R., Szőke, A., Deshpande, S., Zhu, A., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2038372 · Cited by 3
Self-citation
Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry
Baggio, D., Wellard, C. J., Chung, E., Talaulikar, D., Keane, C., Opat, S., Giri, P., Minson, A. G., Cheah, C. Y., Armytage, T., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2157676 · Cited by 3
Oncoral Follow-Up for Outpatients Treated with Oral Anticancer Drugs Assessed by Relative Dose Intensity
Larbre, V., Ranchon, F., Maucort‐Boulch, D., Coz, E., Herledan, C., Caffin, A.-G., Baudouin, A., Maire, M., Romain‐Scelle, N., Vacheron, C., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18040565 · Cited by 2
Research Progress in Secondary Tumors of Indolent B-Cell Lymphoma
周, 书. (2021) · Advances in Clinical Medicine · doi:10.12677/acm.2021.119595 · Cited by 2
Bruton’s tyrosine kinase inhibitor associated localized extremity edema and erythema
Meledathu, S., Chu, P., Feldman, T. A., Goy, A. H., & Rosenstein, R. K. (2024) · JAAD Case Reports · doi:10.1016/j.jdcr.2024.10.001 · Cited by 2
Drug-induced herpes zoster: a pharmacovigilance analysis of FDA adverse event reports from 2004 to 2024
Xia, J., Zhang, J., Zhu, H., & Ding, L. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1565480 · Cited by 2

Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Coutre, S. E., Byrd, J. C., Hillmen, P., Barrientos, J. C., Barr, P. M., Devereux, S., Robak, T., Kipps, T. J., Schuh, A., Moreno, C., et al. (2016) · Blood · doi:10.1182/blood.v128.22.4383.4383 · Cited by 8
Self-citation
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma
O'Brien, S. M., Hillmen, P., Coutre, S. E., Barr, P. M., Fraser, G. A. M., Tedeschi, A., Burger, J. A., Dilhuydy, M., Heß, G., Moreno, C., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.06.016 · Cited by 84
Self-citation
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Sharman, J. P., Wierda, W. G., Zhao, W., Heerema, N. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2856 · Cited by 193
Self-citation
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
O'Brien, S. M., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Sharman, J. P., Wierda, W. G., Jones, J. A., Zhao, W., et al. (2018) · Blood · doi:10.1182/blood-2017-10-810044 · Cited by 387
Self-citation
Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study
Janssens, A. M., Berneman, Z. N., Offner, F. C., Snauwaert, S., Mineur, P., Vanstraelen, G., Meers, S., Spoormans, I., Bron, D., Broek, I. V., et al. (2022) · Clinical Hematology International · doi:10.1007/s44228-022-00020-8 · Cited by 16

Authors: Coutre, S. E., Byrd, J. C., Hillmen, P., Barrientos, J. C., Barr, P. M., Devereux, S., Robak, T., Kipps, T. J., Schuh, A., Moreno, C., Furman, R. R., Burger, J. A., O’Dwyer, M., Ghia, P., Valentino, R., Chang, S., Dean, J. P., James, D. F., & O’Brien, S. M.
Affiliations: Stanford Medicine (US)
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
Leeds Cancer Centre, St. James’s Institute of Oncology, Leeds, United Kingdom;
Hofstra University (US)
University of Rochester Medicine (US)
National Health Service (GB)
Medical University of Lodz (PL)
University of California San Diego (US)
National Institute for Health and Care Research (GB)
Universitat Autònoma de Barcelona (ES)
NewYork–Presbyterian Hospital (US)
The University of Texas MD Anderson Cancer Center (US)
University College Hospital Galway, Galway, Ireland;
Vita-Salute San Raffaele University (IT)
Pharmacyclics (United States) (US)
Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA
ORCID: Coutre, Steven E.
Byrd, John C.
Hillmen, Peter
Barrientos, Jacqueline C.
Barr, Paul M.
Devereux, Stephen
Robak, Tadeusz
Kipps, Thomas J.
Schuh, Anna
Moreno, Carol
Furman, Richard R.
Burger, Jan A.
O’Dwyer, Michael
Ghia, Paolo
Dean, James P.
James, Danelle F.
Venue: Blood Advances
Publisher: American Society of Hematology
Published: 2019-06-13
Volume: 3
Issue: 12
Pages: 1799-1807
ISSN: 2473-9529 (ISSN-L)
2473-9537
DOI: 10.1182/bloodadvances.2018028761
PMC: PMC6595265
OpenAlex: W2952939985
Cited by: 134
References: 31
Citations by year: 2026: 6 · 2025: 22 · 2024: 9 · 2023: 17 · 2022: 23 · 2021: 26 · 2020: 27 · 2019: 3
FWCI: 10.85
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by-nc-nd
Locations: Blood Advances (publishedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, public-domain)
eScholarship (California Digital Library) (submittedVersion, cc-by)
eScholarship (California Digital Library) (submittedVersion)
Funders: Pharmacyclics
National Cancer Institute (R35CA197734, P30CA016672)
Topics: Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords: ibrutinib, chronic lymphocytic leukemia, long-term safety, BTK inhibitors, adverse events, diarrhea, fatigue, neutropenia, pneumonia, hypertension, atrial fibrillation, dose reduction, treatment discontinuation, monotherapy
MeSH terms: Adenine, Adult, Aged, Aged, 80 and over, Anemia, Atrial Fibrillation, Diarrhea, Drug Tolerance, Fatigue, Female, Follow-Up Studies, Hemorrhage, Humans, Hypertension, Infections, Male, Middle Aged, Neutropenia, Piperidines, Pneumonia, Pyrazoles, Pyrimidines, Safety, Leukemia, Lymphocytic, Chronic, B-Cell, Prevalence, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks